stockportfolio.pro
Sotera Health Company (SHC)
Healthcare · Diagnostics & Research · NasdaqGS
Sotera Health Company revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $778.33M | $818.16M | $931.48M | $1.00B | $1.05B | $1.10B | $1.16B |
| Gross profit | $395.43M | $443.57M | $518.67M | $557.00M | $577.16M | $602.29M | $645.53M |
| Net income | $-20.85M | $-38.62M | $116.88M | $-233.57M | $51.38M | $44.40M | $77.95M |
| Net margin | -2.7% | -4.7% | 12.5% | -23.3% | 4.9% | 4.0% | 6.7% |
Source: Sotera Health Company SEC filings (10-K).
What growth is priced into SHC stock?
At today's market cap of $4.66B, Sotera Health Company is priced for free-cash-flow growth of about 13.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $149.18M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 17.3%/yr over the last five fiscal years and revenue 7.3%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 7 years of Sotera Health Company financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SHC in your portfolio →
Sotera Health Company financial history by metric
About Sotera Health Company
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Sotera Health Company — frequently asked questions
What is Sotera Health Company's revenue?
Sotera Health Company (SHC) reported revenue of $1.16B for fiscal year 2025, up 5.7% from the prior year, according to its SEC filings.
Is Sotera Health Company profitable?
Yes. SHC earned net income of $77.95M in fiscal 2025, a net margin of 6.7%.
What is SHC's P/E ratio?
Sotera Health Company trades at a price-to-earnings ratio of about 39.9 based on the latest data in our nightly-refreshed cache.
How fast is Sotera Health Company growing?
SHC's revenue grew at roughly 7.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Sotera Health Company have?
As of fiscal year 2025, SHC carried roughly $2.14B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Sotera Health Company's gross margin?
SHC's gross margin was 55.5% in fiscal 2025 — gross profit of $645.53M on revenue of $1.16B.
What is Sotera Health Company's market cap?
Sotera Health Company (SHC) has a market capitalization of about $4.66B, based on the latest data in our nightly-refreshed cache.
When does Sotera Health Company's fiscal year end?
SHC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into SHC stock?
At today's market cap of $4.66B, Sotera Health Company is priced for free-cash-flow growth of about 13.8% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $149.18M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 17.3%/yr over the last five fiscal years and revenue 7.3%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Sotera Health Company's official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.